Silo Pharma, Inc. (SILO) - Q1 2025 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Silo Pharma, Inc. for the period ended March 31, 2025. Silo Pharma is a developmental-stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including PTSD, stress-induced anxiety, fibromyalgia, Alzheimer's disease, and multiple sclerosis. The company operates as a single segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $18,026 | $18,026 |
| Net Loss | $(1,031,437) | $(801,667) |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.28) |
| Operating Cash Flow | $(1,640,300) | $(838,179) |
| Cash and Cash Equivalents | $3,136,880 | $3,905,799 |
| Short-Term Investments | $2,314,550 | $3,174,724 |
| Working Capital | $4,418,858 | $5,455,483 |
| Total Debt | $0 | $0 |
Note: The company reported no long-term debt. Total liabilities consist primarily of accounts payable and deferred revenue.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $229,770 (28.7%) compared to Q1 2024, driven primarily by higher operating expenses.
- Operating Expenses: Total operating expenses rose to $1,110,687 from $896,079. The most significant increase was in Research and Development (R&D), which jumped 86.6% to $593,962 due to increased costs for Investigator-sponsored Study Agreements and third-party vendor projects.
- Revenue Stability: Revenue remained flat at $18,026, derived entirely from the amortization of license fees from a single customer (Aikido Pharma Inc.).
- Liquidity Position: Cash and cash equivalents decreased by approximately $769,000, and short-term investments decreased by approximately $860,000, reflecting the burn rate and investment sales to fund operations.
Outlook, Management Commentary, and Risks
- Liquidity and Going Concern: Management states that positive working capital mitigates historical doubts about the company's ability to continue as a going concern. They believe current cash and short-term investments are sufficient to meet obligations for at least twelve months from the filing date.
- Product Pipeline Progress:
- SPC-15 (PTSD/Anxiety): Completed first dosing in an IND-enabling GLP-compliant toxicology study in early March 2025; aiming for an IND submission in 2025.
- SP-26 (Fibromyalgia): Initial animal studies began in early 2025 to evaluate dosage and time release.
- SPC-14 (Alzheimer's) & SPU-16 (MS): Remain in preclinical stages.
- Risks: Key risks include the need for additional financing to fund operations and clinical trials, the timing and costs of clinical development, regulatory approval uncertainties, and reliance on a single licensee for current revenue.
- Capital Structure: The company has no treasury stock outstanding as of March 31, 2025, having cancelled all repurchased shares in 2024. There are approximately 2.2 million warrants outstanding.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.45M in liquid assets (cash + short-term investments) against the current burn rate of ~$1.6M per quarter in operating cash usage.
- R&D Spend Efficiency: Review the specific milestones achieved for the 86.6% increase in R&D spending to ensure alignment with the IND submission timeline for SPC-15.
- Revenue Concentration: Confirm the status of the Aikido Pharma license agreement, which accounts for 100% of current revenue.
- Future Financing Needs: Assess the likelihood of dilution or debt issuance required to fund the transition from preclinical to clinical trials for the lead candidates.
- License Obligations: Review the Columbia University and University of Maryland license agreements for upcoming milestone payments or royalty triggers.